Game changing session 5 : Game changing session: Overall survival (OS) by circulating tumor DNA (ctDNA) status in patients with post-operative muscle-invasive urothelial carcinoma (MIUC) treated with atezolizumab (atezo): update from IMvigor010

Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC) (Trial in Progress)

Game changing session 3 : Game changing session: Clinical Trial Protocol for LuTectomy: A Single-arm Study of the Dosimetry, Safety, and Potential Benefit of 177 Lu-PSMA-617 Prior to Prostatectomy

Game changing session 3 : Game changing session: Randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for unfavorable intermediate- and high-risk prostate cancer

Game changing session 6 : Game changer session: Overall Survival With Darolutamide Versus Placebo in Combination With Androgen-deprivation Therapy and Docetaxel by Stratification Factors in the Phase 3 ARASENS Trial

Game changing session 1 : Game changing session: Complications with open versus robotic-assisted partial nephrectomy (OpeRa) in patients with intermediate/high-complexity kidney tumours

Game changing session 2 : Game changing session: Pembrolizumab (pembro) as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Updated results from the 30-month follow-up of KEYNOTE-564

Game changing session 5 : Game changing session: Exploratory endpoints from PROpel: A Phase III trial of abiraterone + olaparib vs. abiraterone + placebo in 1st line metastatic castration-resistant prostate cancer

Early oncologic outcomes of open vs. robot-assisted radical cystectomy with totally intracorporeal urinary diversion: Single centre prospective randomised controlled trial

PSMA-flare after ADT evaluated with 18F-PSMA-1007 PET/CT in hormone-sensitive metastatic prostate cancer: Possible predictor of tumour aggressiveness?

Sustained castration to < 20 ng/dl for relugolix vs. leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study

Open vs. robot-assisted radical cystectomy with totally intracorporeal urinary diversion: functional outcomes comparison from a single centre randomised controlled trial

Should we limit robot-assisted radical cystectomy with totally intracorporeal urinary diversion to neobladder patients? Head to head comparison of outcomes between robotic vs. open ileal conduit and robotic vs. open neobladder

First line avelumab in PD-L1+ve metastatic or locally advanced Urothelial Cancer (aUC) patients unfit for cisplatin: The ARIES trial

Predictors of early health-related quality of life deterioration in patients receiving radical cystectomy with urinary diversion: Results from a single centre randomized controlled trial